A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Stella acts as an intermediary. Researcher contact info is never exposed.